What the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.29%Below 5Y avg (0.54%)
Annual Rate
CNY 0.04Paid annual
Payout Ratio
28.5%Sustainable
Last Ex-Dividend
Jun 23, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
14.07BCNY
2.11B · vs all stocks (USD)
Updated Oct 22, 2026
Trailing P/E
99.85x
vs Biotechnology peers
Updated Oct 22, 2026
Revenue (TTM)
1.53BCNY
229.82M · vs all stocks (USD)
Updated Oct 22, 2026
Profit Margin
9.38%
vs Biotechnology peers
Updated Oct 22, 2026
Beta
0.6650x
vs all stocks
Updated Oct 22, 2026
52-Week Change
18.76%
vs all stocks
Updated Oct 22, 2026
Market Capitalization
14.07BCNY
2.11B · vs all stocks (USD)
Updated Oct 22, 2026
Enterprise Value
12.69BCNY
1.90B · vs all stocks (USD)
Updated Oct 22, 2026
Trailing P/E
99.85x
vs Biotechnology peers
Updated Oct 22, 2026
Forward P/E
54.08x
vs Biotechnology peers
Updated Oct 22, 2026
Price to Sales (TTM)
9.31x
vs Biotechnology peers
Updated Oct 22, 2026
Price to Book (MRQ)
2.61x
vs Biotechnology peers
Updated Oct 22, 2026
Enterprise to Revenue
8.28x
vs Biotechnology peers
Updated Oct 22, 2026
Enterprise to EBITDA
41.40x
vs Biotechnology peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 29.73×.Updated Oct 22, 2026
Gross Margin
54.28%
vs Biotechnology peers
Updated Oct 22, 2026
Profit Margin
9.38%
vs Biotechnology peers
Updated Oct 22, 2026
Operating Margin
6.92%
vs Biotechnology peers
Updated Oct 22, 2026
Return on Assets (TTM)
0.57%
vs Biotechnology peers
Updated Oct 22, 2026
Return on Equity (TTM)
2.70%
vs Biotechnology peers
Updated Oct 22, 2026
Revenue (TTM)
1.53BCNY
229.82M · vs all stocks (USD)
Updated Oct 22, 2026
Revenue per Share (TTM)
1.36CNYUpdated Oct 22, 2026
Quarterly Revenue Growth
53.00%
vs Biotechnology peers
Updated Oct 22, 2026
Gross Profit (TTM)
806.64MCNY
120.91M · vs all stocks (USD)
Updated Oct 22, 2026
EBITDA (TTM)
426.91MCNY
63.99M · vs all stocks (USD)
Updated Oct 22, 2026
Net Income (TTM)
143.79MCNY
21.55M · vs all stocks (USD)
Updated Oct 22, 2026
Quarterly Earnings Growth (YoY)
16.61%
vs Biotechnology peers
Updated Oct 22, 2026
Operating Cash Flow (TTM)
278.20MCNY
41.70M · vs all stocks (USD)
Updated Oct 22, 2026
Levered Free Cash Flow (TTM)
-53.66MCNY
-8.04M · vs all stocks (USD)
Updated Oct 22, 2026
Trailing Annual Dividend Rate
0.0370CNYUpdated Oct 22, 2026
Trailing Annual Dividend Yield
0.29%
vs all stocks
Updated Oct 22, 2026
5-Year Average Dividend Yield
0.54%
vs all stocks
Updated Oct 22, 2026
Payout Ratio
28.46%
vs Biotechnology peers
Updated Oct 22, 2026
Minority Interest (Equity)
182.81MCNYFY2025 · Dec 31, 2025
Revenue
1.40BCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
648.89MCNYFY2025 · Dec 31, 2025
Gross Profit
747.53MCNYFY2025 · Dec 31, 2025
Operating Income
119.75MCNY
17.95M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
104.62MCNYFY2025 · Dec 31, 2025
Income Tax Expense
9.11MCNYFY2025 · Dec 31, 2025
Net Income
95.51MCNYFY2025 · Dec 31, 2025
EBIT
105.09MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
426.91MCNYFY2025 · Dec 31, 2025
Research & Development
131.09MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
368.37MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
23.36MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
51.17MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
470.25KCNYFY2025 · Dec 31, 2025
EPS (Basic)
0.0900CNYFY2025 · Dec 31, 2025
EPS (Diluted)
0.0900CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
1.11BSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
1.11BSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
95.51MCNYFY2025 · Dec 31, 2025
Minority Interests (P&L)
4.61MCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
75.07MCNYFY2025 · Dec 31, 2025
Free Cash Flow
-37.04MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
616.75MCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
95.51MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
-40.01MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
30.48MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-10.91MCNYFY2025 · Dec 31, 2025
Capital Expenditures
-112.10MCNYFY2025 · Dec 31, 2025
Net Acquisitions
183.23KCNYFY2025 · Dec 31, 2025
Purchase of Investments
-138.25MCNYFY2025 · Dec 31, 2025
Sale of Investments
198.31MCNYFY2025 · Dec 31, 2025
Other Investing Activity
-153.99MCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
-205.85MCNYFY2025 · Dec 31, 2025
Long-term Debt Payments
-15.00MCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-33.32MCNYFY2025 · Dec 31, 2025
Other Financing Charges
-259.13MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
-307.44MCNYFY2025 · Dec 31, 2025
Shares Outstanding
1.11BSharesUpdated Oct 22, 2026
Float Shares
880.72MSharesUpdated Oct 22, 2026
% Held by Insiders
21.53%
vs all stocks
Updated Oct 22, 2026
% Held by Institutions
8.94%
vs all stocks
Updated Oct 22, 2026
Total Cash (MRQ)
1.67BCNY
250.32M · vs all stocks (USD)
Updated Oct 22, 2026
Total Cash per Share (MRQ)
1.53CNYUpdated Oct 22, 2026
Total Debt (MRQ)
101.28MCNY
15.18M · vs all stocks (USD)
Updated Oct 22, 2026
Total Debt to Equity (MRQ)
0.0183x
vs Biotechnology peers
Updated Oct 22, 2026
Current Ratio (MRQ)
4.21x
vs Biotechnology peers
Updated Oct 22, 2026
Book Value per Share (MRQ)
4.96CNYUpdated Oct 22, 2026
Total Assets
6.61BCNY
991.01M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
2.34BCNYFY2025 · Dec 31, 2025
Total Liabilities
1.06BCNYFY2025 · Dec 31, 2025
Total Non-current Assets
4.27BCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
340.18MCNYFY2025 · Dec 31, 2025
Total Current Liabilities
720.53MCNYFY2025 · Dec 31, 2025
Cash
1.23BCNYFY2025 · Dec 31, 2025
Cash Equivalents
30.71MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
1.26BCNYFY2025 · Dec 31, 2025
Other Short-term Investments
120.11MCNYFY2025 · Dec 31, 2025
Accounts Receivable
591.09MCNYFY2025 · Dec 31, 2025
Inventory
269.13MCNYFY2025 · Dec 31, 2025
Accounts Payable
256.02MCNYFY2025 · Dec 31, 2025
Short-term Debt
1.43MCNYFY2025 · Dec 31, 2025
Other Current Liabilities
7.54MCNYFY2025 · Dec 31, 2025
Long-term Debt
146.69KCNYFY2025 · Dec 31, 2025
Common Stock (Book)
1.11BCNYFY2025 · Dec 31, 2025
Retained Earnings
3.24BCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
5.55BCNY
832.02M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Treasury Stock
242.30MCNYFY2025 · Dec 31, 2025
52-Week Low
10.21CNYUpdated Oct 22, 2026
52-Week High
19.00CNYUpdated Oct 22, 2026
52-Week Change
18.76%
vs all stocks
Updated Oct 22, 2026
Beta
0.6650x
vs all stocks
Updated Oct 22, 2026
50-Day MA
12.20CNYUpdated Oct 22, 2026
200-Day MA
13.64CNYUpdated Oct 22, 2026
Avg 10-Day Volume
17.18MSharesUpdated Oct 22, 2026
Avg 30-Day Volume
12.26MSharesUpdated Oct 22, 2026
Diluted EPS (TTM)
0.1300CNYUpdated Oct 22, 2026
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 9.2: safe zoneNotable
Altman Z-Score: 9.20
High earnings qualityNotable
Earnings Quality Score: 0.53
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2.11B, above the global median of $1.14BNotable
Market cap (USD): 2,108,664,045.642Global Median: 1,137,180,293.291
Companies that share the same coordination system — how they create, deliver, or capture value.